Baird analyst David Koning lowered the firm’s price target on Genpact to $44 from $48 and keeps an Outperform rating on the shares. The firm said Q2 results were mixed as EPS beat but revenue missed Street mildly.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on G: